Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Monday, October 14, 2024 · 751,577,434 Articles · 3+ Million Readers

MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference

August 07, 2024 --

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at Canaccord Genuity’s 44th Annual Growth Conference:

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following the event.

About MindMed

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.

Powered by EIN Presswire

Distribution channels:

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Submit your press release